Cevidra

What Cevidra does

Cevidra is a privately-held French pharmaceutical services firm headquartered in Grasse, France, founded in 2006 and operating with 11–50 employees under founder-CEO Stephane Destaing. The company operates as an Exploitant, a regulated status that legally allows it to market and distribute medicinal products in France on behalf of Marketing Authorization Holders not established in France. It provides an integrated continuum of pharmaceutical services — Early Access Programs, Compassionate Use / Named Patient Programs, Market Access, Post-Market Surveillance, Supply Chain Optimization, Promotion & Sales, and Regulatory Compliance — targeted at international and domestic pharmaceutical, biotech, ATMP, blood-product, and orphan-drug developers seeking entry into the French hospital market.

Cevidra's offerings are specialized around high-value, regulated therapeutic categories: blood-derived products, Advanced Therapy Medicinal Products (cell and gene therapies), and orphan drugs for rare diseases. Operationally, the firm maintains direct relationships with major French public hospital purchasing platforms (including RESPAN and UNIHA), responds to public tenders for hospital procurement, runs a 24/7 distribution operation with same-day shipping for orders placed before 4 p.m. and next-day delivery, and provides secondary packaging and batch release services. Pharmacist-led teams handle quality complaints, medical information requests, pharmacovigilance, and post-market surveillance. Industry association memberships (MabDesign, Eurobiomed, EUCOPE, AMLIS) embed Cevidra in the French and European biotherapy and SME health ecosystems.

Cevidra is a B2B professional-services business with quote-based, scope-dependent pricing; revenue mechanics are not publicly disclosed. The firm generates revenue across multiple customer segments — pharmaceutical manufacturers, biotech firms, ATMP developers, orphan-drug manufacturers, and blood-product companies — but is geographically concentrated entirely in France (Europe). There are no disclosed funding rounds, no parent company, and no indications of external private equity or venture capital backing; Cevidra appears to be an independent, founder/management-owned private company.

Name

Cevidra

Legal name

Cevidra

Website

https://cevidra.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Cevidra is a French pharmaceutical services firm that acts as a regulated Exploitant, providing early access, market access, supply chain, and post-market surveillance services for high-value hospital drugs, including ATMPs, orphan drugs, and blood-derived products, primarily serving international and domestic pharma manufacturers entering the French hospital market.

Ownership category

akta.pro rank

Headquarters

HQ city

Grasse

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Pharmaceutical Services: Cevidra generates revenue through comprehensive pharmaceutical services including early access programs, compassionate use programs, market access consulting, regulatory compliance, supply chain optimization, and promotion & sales services for medicinal products targeting the French hospital market.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Cevidra is a French pharmaceutical services company founded in 2006 and based in Grasse, France. The company provides regulatory and operational support for marketing high-value drugs intended for hospital use in France, holding the Exploitant status required by French authorities. Cevidra specializes in blood-derived products, Advanced Therapy Medicinal Products (ATMPs), and orphan drugs, with over 15 years of focused experience in navigating complex regulatory pathways.

Product overview

Cevidra is an independent French pharmaceutical services company offering integrated continuum services for medicinal products to access the French market. The company operates as an Exploitant (marketing authorization holder representative) and provides a unified portfolio of services including Early Access Programs (EAP), Compassionate Use Programs, Market Access, Post-Market Surveillance, Supply Chain Optimization, Promotion & Sales, and Regulatory Compliance. Cevidra specializes in high value-added drugs for hospital use, with particular expertise in blood-derived products, ATMPs (Advanced Therapy Medicinal Products), and orphan drugs for rare diseases. The company also offers Tender Management services for the French public hospital procurement system.

Differentiator

Problem solved

Functional benefit

Products and services

• Exploitant status services for hospital pharmaceuticals Provision of Cevidra's French Exploitant regulatory status to pharmaceutical manufacturers seeking to market high-value hospital drugs in France. This service enables clients to commercialize hospital pharmaceuticals without holding the Exploitant license themselves.
• Early access program (ATU) management Regulatory and operational support for Authorization for Temporary Use (ATU) early access programs in France, enabling pharmaceutical companies to provide hospital drugs to patients before full market authorization.
• ATMP commercialization services Regulatory pathway navigation and operational support for Advanced Therapy Medicinal Products (ATMPs) intended for the French hospital market.
• Orphan drug market access services End-to-end regulatory and market access support for orphan drugs targeting the French hospital market, leveraging Cevidra's specialized expertise in rare disease therapies.
• Blood-derived product regulatory services Specialized regulatory and compliance services for blood-derived pharmaceuticals marketed through French hospitals.

Quantifiable outcome

• Processing hospital orders until 4 p.m. for same-day shipping with delivery before noon the next day
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered minor.

• MabDesignminorOthersMabDesign is a biotherapy expert organization. Cevidra's partnership provides networking and visibility within the biotherapy and advanced therapy medicinal products ecosystem in France.
• EurobiomedminorOthersEurobiomed is a health innovation cluster. Cevidra's membership supports networking with other healthcare innovators and stakeholders in the Mediterranean region.
• EUCOPE (European Confederation of Pharmaceutical Entrepreneurs AISBL)minorOthersEUCOPE represents pharmaceutical entrepreneurs at the European level. Cevidra's membership provides advocacy representation and regulatory intelligence at the EU level.
• AMLISminorOthersAMLIS is an organization supporting French SMEs for health. Cevidra's membership provides access to resources and support for small and medium-sized enterprises in the health sector.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Voisin Consulting Life Sciences: France-based regulatory and market access consultancy serving pharma and biotech with EU/French HTA, clinical development, and pharmacovigilance support — directly comparable to Cevidra's regulatory + market access + pharmacovigilance stack for the French hospital market.
• PharmaLex (now part of Cencora/World Courier): European regulatory affairs, market access and pharmacovigilance services firm comparable to Cevidra's Exploitant-style role, serving pharma/biotech sponsors seeking to commercialize in major EU markets including France.
• PrimeVigilance: Specialized pharmacovigilance and post-market surveillance service provider for pharma and biotech — directly comparable to Cevidra's Post-Market Surveillance and medical information offerings for the French market.
• Aixial Group: French-headquartered CRO and clinical/pharmaceutical services firm supporting biotech and pharma across regulatory and clinical operations — comparable as a France-anchored pharma services specialist competing in overlapping regulatory and market access work.

Regional players

• Staphyt: France-based CRO offering regulatory, clinical, and product development services to pharma and crop science clients — comparable in French pharma regulatory services scope, though with a different vertical mix.

Broad incumbents

• IQVIA: Global life sciences services leader spanning clinical, real-world evidence, regulatory, market access, and commercial services in France and globally — a broad incumbent whose market access and commercial offerings overlap with Cevidra's promotion & sales and market access services.
• ICON plc: Global CRO with a sizeable market access, regulatory and pharmacovigilance practice across Europe — comparable as a broad incumbent competing for the same pharma/biotech regulatory and lifecycle management budgets that Cevidra targets in France.
• Syneos Health: Global clinical and commercial pharma services firm with regulatory, market access, and pharmacovigilance offerings — comparable in the commercial services overlay that competes with Cevidra's promotion & sales work for French launches.
• Catalent: Global CDMO and pharma services provider with development, manufacturing, and commercial supply capabilities in Europe — a broad incumbent whose secondary packaging, batch release, and distribution services overlap directly with Cevidra's supply chain optimization stack.
• Eurofins Scientific: European-headquartered lab services and pharma services group with product testing, regulatory, and distribution-adjacent offerings — a broad incumbent operating across the pharma value chain with comparable reach into French pharmaceutical clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cevidra